|
|
|
|
Pharmacogenetic risk scores for perindopril clinical and cost effectiveness in stable coronary artery disease: When are we ready to implement?
|
|
|
|
|
|
|
|
نویسنده
|
luzum j.a. ,lanfear d.e.
|
|
منبع
|
journal of the american heart association - 2016 - دوره : 5 - شماره : 3
|
|
چکیده
|
[no abstract available]
|
|
کلیدواژه
|
Angiotensin-converting enzyme inhibitor; Cardiovascular disease; Editorials; Pharmacogenetics
|
|
آدرس
|
ohio state university,college of medicine,center for pharmacogenomics,columbus,oh, United States, heart and vascular institute,henry ford hospital,detroit,mi,united states,center for health policy and health services research,henry ford hospital,detroit,mi, United States
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|